1
|
Zhao S, Yang H, Liu X, Ma S, He P, Sun Z, Jia D, Colombo P, Zhou Y. Effect of PFDS on the immobilization of Cs + by metakaolin-based geopolymers in complex environments. J Environ Manage 2024; 356:120616. [PMID: 38518493 DOI: 10.1016/j.jenvman.2024.120616] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/25/2023] [Revised: 02/20/2024] [Accepted: 03/10/2024] [Indexed: 03/24/2024]
Abstract
Metakaolin-based geopolymers are very promising materials for improving the safety of low and intermediate level radioactive waste disposal, with respect to ordinary Portland cement, due to their excellent immobilization performance for Cs+ and superior chemical stability. However, their application is limited by the fact that the leaching behavior of Cs+ is susceptible to the presence of other ions in the environment. Here, we propose a way to modify a geopolymer using perfluorodecyltriethoxysilane (PDFS), successfully reducing the leaching rate of Cs+ in the presence of multiple competitive cations due to blocking the diffusion of water. The leachability index of the modified samples in deionized water and highly concentrated saline water reached 11.0 and 8.0, respectively. The reaction mechanism between PDFS and geopolymers was systematically investigated by characterizing the microstructure and chemical bonding of the material. This work provides a facile and successful approach to improve the immobilization of Cs ions by geopolymers in real complex environments, and it could be extended to further improve the reliability of geopolymers used in a range of applications.
Collapse
Affiliation(s)
- Shengjian Zhao
- Institute for Advanced Ceramics, School of Materials Science and Engineering, Harbin Institute of Technology, Harbin, PR China; Key Laboratory of Advanced Structural-Functional Integration Materials & Green Manufacturing Technology, Harbin Institute of Technology, Harbin, PR China
| | - Hualong Yang
- Institute for Advanced Ceramics, School of Materials Science and Engineering, Harbin Institute of Technology, Harbin, PR China; Key Laboratory of Advanced Structural-Functional Integration Materials & Green Manufacturing Technology, Harbin Institute of Technology, Harbin, PR China
| | - Xuehui Liu
- Institute for Advanced Ceramics, School of Materials Science and Engineering, Harbin Institute of Technology, Harbin, PR China; Key Laboratory of Advanced Structural-Functional Integration Materials & Green Manufacturing Technology, Harbin Institute of Technology, Harbin, PR China
| | - Siqi Ma
- Institute for Advanced Ceramics, School of Materials Science and Engineering, Harbin Institute of Technology, Harbin, PR China; Key Laboratory of Advanced Structural-Functional Integration Materials & Green Manufacturing Technology, Harbin Institute of Technology, Harbin, PR China
| | - Peigang He
- Institute for Advanced Ceramics, School of Materials Science and Engineering, Harbin Institute of Technology, Harbin, PR China; Key Laboratory of Advanced Structural-Functional Integration Materials & Green Manufacturing Technology, Harbin Institute of Technology, Harbin, PR China.
| | | | - Dechang Jia
- Institute for Advanced Ceramics, School of Materials Science and Engineering, Harbin Institute of Technology, Harbin, PR China; Key Laboratory of Advanced Structural-Functional Integration Materials & Green Manufacturing Technology, Harbin Institute of Technology, Harbin, PR China
| | - Paolo Colombo
- Department of Industrial Engineering, University of Padova, Padova, Italy; Department of Materials Science and Engineering, The Pennsylvania State University, Philadelphia, USA
| | - Yu Zhou
- Institute for Advanced Ceramics, School of Materials Science and Engineering, Harbin Institute of Technology, Harbin, PR China; Key Laboratory of Advanced Structural-Functional Integration Materials & Green Manufacturing Technology, Harbin Institute of Technology, Harbin, PR China; School of Materials Science and Engineering, Harbin Institute of Technology (Shenzhen), Shenzhen, PR China
| |
Collapse
|
2
|
Barletta B, Corinti S, Maranghi F, Tait S, Tassinari R, Martinelli A, Longo A, Longo V, Colombo P, Di Felice G, Butteroni C. The environmental pollutant BDE-47 modulates immune responses in invitro and in vivo murine models. Chemosphere 2024; 349:140739. [PMID: 38000557 DOI: 10.1016/j.chemosphere.2023.140739] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/10/2023] [Revised: 11/13/2023] [Accepted: 11/14/2023] [Indexed: 11/26/2023]
Abstract
2,2',4,4'-tetra-bromodiphenyl ether (BDE-47) is widespread in the environment and biological samples. Its association with health risks is an increasing concern, yet information on BDE-47 immunotoxicity remains limited. This study investigated the impact of BDE-47 on innate and adaptive immune responses through in vitro and in vivo approaches. BDE-47's capacity to directly induce cell responses and modulate responses induced by known stimuli was studied in vitro using the RAW 264.7 murine macrophage cell line and spleen-derived lymphocytes, and in vivo using keyhole limpet hemocyanin (KLH)-immunized BALB/c mice orally administered (28 d) at dose levels (7.5, 15.0 and 30 mg/kg/bw/d) derived from relevant toxicokinetic data from rodent models. RAW 264.7 cells stimulated with lipopolysaccharide (LPS) and exposed to BDE-47 exhibited unchanged cell viability but decreased release of interleukin (IL)-6. Primary splenocytes from naïve mice stimulated with anti-CD3/anti-CD28 antibodies and exposed to BDE-47 showed a significant decrease of IL-17 A and IFNγ production. In vivo data showed that BDE-47 significantly reduced the KLH-specific antibody response. A generally decreasing trend of IFNγ, IL-10 and IL-5 production was observed after in vitro antigen-specific restimulation of spleen cells. Histopathological effects on liver, spleen, small intestine and thyroid were detected at the highest dose in the absence of general toxicity. In addition, the expression of Mm_mir155 and Mm_let7a was induced in livers of exposed mice. The data obtained in this study suggest that exposure to BDE-47 may perturb innate and adaptive immune responses, thus possibly decreasing resistance to bacterial and viral infections.
Collapse
Affiliation(s)
- Bianca Barletta
- National Center for Drug Research and Evaluation, Istituto Superiore di Sanità, Rome, Italy.
| | - Silvia Corinti
- National Center for Drug Research and Evaluation, Istituto Superiore di Sanità, Rome, Italy.
| | - Francesca Maranghi
- Center for Gender-Specific Medicine, Istituto Superiore di Sanità, Rome, Italy.
| | - Sabrina Tait
- Center for Gender-Specific Medicine, Istituto Superiore di Sanità, Rome, Italy.
| | - Roberta Tassinari
- Center for Gender-Specific Medicine, Istituto Superiore di Sanità, Rome, Italy.
| | - Andrea Martinelli
- Center for Animal Research and Welfare, Istituto Superiore di Sanità, Rome, Italy.
| | - Alessandra Longo
- Institute for Biomedical Research and Innovation, National Research Council (IRIB-CNR), Palermo, Italy.
| | - Valeria Longo
- Institute for Biomedical Research and Innovation, National Research Council (IRIB-CNR), Palermo, Italy.
| | - Paolo Colombo
- Institute for Biomedical Research and Innovation, National Research Council (IRIB-CNR), Palermo, Italy.
| | - Gabriella Di Felice
- National Center for Drug Research and Evaluation, Istituto Superiore di Sanità, Rome, Italy.
| | - Cinzia Butteroni
- National Center for Drug Research and Evaluation, Istituto Superiore di Sanità, Rome, Italy.
| |
Collapse
|
3
|
Vinogradsky A, Ning Y, Kurlansky P, Kirschner M, Yuzefpolskaya M, Colombo P, Sayer G, Uriel N, Naka Y, Takeda K. Less is better? Comparing effects of median sternotomy and thoracotomy surgical approaches for left ventricular assist device implantation on postoperative outcomes and valvulopathy. J Thorac Cardiovasc Surg 2024; 167:731-743.e3. [PMID: 36008179 PMCID: PMC9669283 DOI: 10.1016/j.jtcvs.2022.04.036] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/27/2021] [Revised: 04/06/2022] [Accepted: 04/25/2022] [Indexed: 10/18/2022]
Abstract
OBJECTIVE Our objective was to compare outcomes after left ventricular assist device implantation performed via median sternotomy or lateral thoracotomy. METHODS We retrospectively analyzed 222 adult patients with the HeartMate3 (Abbott Lab) left ventricular assist device implanted between November 2014 and November 2021. Outcomes stratified by surgical approach were evaluated in propensity score-matched groups. The primary outcome was 1-year survival. Secondary outcomes included in-hospital morbidity and mortality, readmissions, and significant valvular regurgitation. RESULTS Our cohort consisted of 60 patients (27%) who underwent lateral thoracotomy and 162 patients (73%) who underwent median sternotomy. Propensity score matching compared 45 patients who underwent lateral thoracotomy with 68 patients who underwent median sternotomy. There were no differences in intensive care unit or hospital stay duration (median, 10 vs 11 days, P = .58; 46 vs 40 days, P = .279), time to extubation (median, 2 days, P = .627), vasoactive-inotropic scores at intensive care unit arrival (18.20 vs 16.60, P = .654), or in-hospital mortality (2 [5%] vs 4 [6.1%] patients, P = 1). One-year survival (95.56% vs 90.61%, P = .48) and all-cause hospital readmission rate (Gray's test: P = .532) were also comparable. Patients who underwent lateral thoracotomy had significantly less early right ventricular failure (24.4% vs 53.7%, P = .004), although they had more follow-up tricuspid regurgitation (17.6% vs 0%, P = .030) and volume overload readmissions (Gray's test: P = .0005). CONCLUSIONS Our data suggest that lateral thoracotomy is a safe although not necessarily superior alternative to median sternotomy for HeartMate 3 implantation in the perioperative and postoperative periods, because it precludes concomitant tricuspid valve repairs and may be associated with increased risk of late tricuspid regurgitation and volume overload readmissions.
Collapse
Affiliation(s)
- Alice Vinogradsky
- Division of Cardiac, Thoracic & Vascular Surgery, Department of Surgery, Columbia University Irving Medical Center, New York, NY
| | - Yuming Ning
- Department of Surgery, Center for Innovation and Outcomes Research, Columbia University Irving Medical Center, New York, NY
| | - Paul Kurlansky
- Department of Surgery, Center for Innovation and Outcomes Research, Columbia University Irving Medical Center, New York, NY
| | - Michael Kirschner
- Division of Cardiac, Thoracic & Vascular Surgery, Department of Surgery, Columbia University Irving Medical Center, New York, NY
| | - Melana Yuzefpolskaya
- Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, NY
| | - Paolo Colombo
- Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, NY
| | - Gabriel Sayer
- Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, NY
| | - Nir Uriel
- Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, NY
| | - Yoshifumi Naka
- Division of Cardiac, Thoracic & Vascular Surgery, Department of Surgery, Columbia University Irving Medical Center, New York, NY
| | - Koji Takeda
- Division of Cardiac, Thoracic & Vascular Surgery, Department of Surgery, Columbia University Irving Medical Center, New York, NY.
| |
Collapse
|
4
|
Aloi N, Drago G, Ruggieri S, Cibella F, Colombo P, Longo V. Extracellular Vesicles and Immunity: At the Crossroads of Cell Communication. Int J Mol Sci 2024; 25:1205. [PMID: 38256278 PMCID: PMC10816988 DOI: 10.3390/ijms25021205] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2023] [Revised: 01/15/2024] [Accepted: 01/17/2024] [Indexed: 01/24/2024] Open
Abstract
Extracellular vesicles (EVs), comprising exosomes and microvesicles, are small membranous structures secreted by nearly all cell types. They have emerged as crucial mediators in intercellular communication, playing pivotal roles in diverse physiological and pathological processes, notably within the realm of immunity. These roles go beyond mere cellular interactions, as extracellular vesicles stand as versatile and dynamic components of immune regulation, impacting both innate and adaptive immunity. Their multifaceted involvement includes immune cell activation, antigen presentation, and immunomodulation, emphasising their significance in maintaining immune homeostasis and contributing to the pathogenesis of immune-related disorders. Extracellular vesicles participate in immunomodulation by delivering a wide array of bioactive molecules, including proteins, lipids, and nucleic acids, thereby influencing gene expression in target cells. This manuscript presents a comprehensive review that encompasses in vitro and in vivo studies aimed at elucidating the mechanisms through which EVs modulate human immunity. Understanding the intricate interplay between extracellular vesicles and immunity is imperative for unveiling novel therapeutic targets and diagnostic tools applicable to various immunological disorders, including autoimmune diseases, infectious diseases, and cancer. Furthermore, recognising the potential of EVs as versatile drug delivery vehicles holds significant promise for the future of immunotherapies.
Collapse
Affiliation(s)
| | | | | | | | - Paolo Colombo
- Institute for Biomedical Research and Innovation, National Research Council of Italy (IRIB-CNR), Via Ugo La Malfa 153, 90146 Palermo, Italy; (N.A.); (G.D.); (S.R.); (F.C.); (V.L.)
| | | |
Collapse
|
5
|
Alogna A, Berboth L, Faragli A, Ötvös J, Lo Muzio FP, di Mauro V, Modica J, Quarta E, Semmler L, Deißler PM, Berger YW, Tran KL, de Marchi B, Longinotti-Buitoni G, Degli Esposti L, Guillot E, Bazile D, Iafisco M, Dotti A, Bang ML, de Luca C, Brandenberger C, Benazzi L, di Silvestre D, de Palma A, Primeßnig U, Hohendanner F, Perna S, Buttini F, Colombo P, Mühlfeld C, Steendijk P, Mauri P, Tschöpe C, Borlaug B, Pieske BM, Attanasio P, Post H, Heinzel FR, Catalucci D. Lung-to-Heart Nano-in-Micro Peptide Promotes Cardiac Recovery in a Pig Model of Chronic Heart Failure. J Am Coll Cardiol 2024; 83:47-59. [PMID: 38171710 DOI: 10.1016/j.jacc.2023.10.029] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/23/2023] [Revised: 10/11/2023] [Accepted: 10/13/2023] [Indexed: 01/05/2024]
Abstract
BACKGROUND The lack of disease-modifying drugs is one of the major unmet needs in patients with heart failure (HF). Peptides are highly selective molecules with the potential to act directly on cardiomyocytes. However, a strategy for effective delivery of therapeutics to the heart is lacking. OBJECTIVES In this study, the authors sought to assess tolerability and efficacy of an inhalable lung-to-heart nano-in-micro technology (LungToHeartNIM) for cardiac-specific targeting of a mimetic peptide (MP), a first-in-class for modulating impaired L-type calcium channel (LTCC) trafficking, in a clinically relevant porcine model of HF. METHODS Heart failure with reduced ejection fraction (HFrEF) was induced in Göttingen minipigs by means of tachypacing over 6 weeks. In a setting of overt HFrEF (left ventricular ejection fraction [LVEF] 30% ± 8%), animals were randomized and treatment was started after 4 weeks of tachypacing. HFrEF animals inhaled either a dry powder composed of mannitol-based microparticles embedding biocompatible MP-loaded calcium phosphate nanoparticles (dpCaP-MP) or the LungToHeartNIM only (dpCaP without MP). Efficacy was evaluated with the use of echocardiography, invasive hemodynamics, and biomarker assessment. RESULTS DpCaP-MP inhalation restored systolic function, as shown by an absolute LVEF increase over the treatment period of 17% ± 6%, while reversing cardiac remodeling and reducing pulmonary congestion. The effect was recapitulated ex vivo in cardiac myofibrils from treated HF animals. The treatment was well tolerated, and no adverse events occurred. CONCLUSIONS The overall tolerability of LungToHeartNIM along with the beneficial effects of the LTCC modulator point toward a game-changing treatment for HFrEF patients, also demonstrating the effective delivery of a therapeutic peptide to the diseased heart.
Collapse
Affiliation(s)
- Alessio Alogna
- Deutsches Herzzentrum der Charité, Department of Cardiology, Angiology and Intensive Care Medicine, Campus Virchow-Klinikum, Berlin, Germany; Berlin Institute of Health at Charité-Universitätsmedizin Berlin, Berlin, Germany; German Centre for Cardiovascular Research, Berlin, Germany.
| | - Leonhard Berboth
- Deutsches Herzzentrum der Charité, Department of Cardiology, Angiology and Intensive Care Medicine, Campus Virchow-Klinikum, Berlin, Germany
| | - Alessandro Faragli
- Deutsches Herzzentrum der Charité, Department of Cardiology, Angiology and Intensive Care Medicine, Campus Virchow-Klinikum, Berlin, Germany
| | - Jens Ötvös
- Deutsches Herzzentrum der Charité, Department of Cardiology, Angiology and Intensive Care Medicine, Campus Virchow-Klinikum, Berlin, Germany
| | - Francesco Paolo Lo Muzio
- Deutsches Herzzentrum der Charité, Department of Cardiology, Angiology and Intensive Care Medicine, Campus Virchow-Klinikum, Berlin, Germany
| | - Vittoria di Mauro
- Institute of Genetic and Biomedical Research, National Research Council of Italy, Milan Unit, Milan, Italy; Humanitas Cardio Center, IRCCS Humanitas Research Hospital, Rozzano (Milan), Italy
| | - Jessica Modica
- Institute of Genetic and Biomedical Research, National Research Council of Italy, Milan Unit, Milan, Italy; Humanitas Cardio Center, IRCCS Humanitas Research Hospital, Rozzano (Milan), Italy
| | - Eride Quarta
- Department of Food and Drugs, University of Parma, Parma, Italy; PlumeStars, Parma, Italy
| | - Lukas Semmler
- Deutsches Herzzentrum der Charité, Department of Cardiology, Angiology and Intensive Care Medicine, Campus Virchow-Klinikum, Berlin, Germany
| | - Peter Maximilian Deißler
- Deutsches Herzzentrum der Charité, Department of Cardiology, Angiology and Intensive Care Medicine, Campus Virchow-Klinikum, Berlin, Germany
| | - Yannic Wanja Berger
- Deutsches Herzzentrum der Charité, Department of Cardiology, Angiology and Intensive Care Medicine, Campus Virchow-Klinikum, Berlin, Germany
| | - Khai Liem Tran
- Deutsches Herzzentrum der Charité, Department of Cardiology, Angiology and Intensive Care Medicine, Campus Virchow-Klinikum, Berlin, Germany
| | | | | | - Lorenzo Degli Esposti
- Institute of Science, Technology and Sustainability for Ceramics (ISSMC), National Research Council, Faenza, Italy
| | | | | | - Michele Iafisco
- Institute of Science, Technology and Sustainability for Ceramics (ISSMC), National Research Council, Faenza, Italy
| | | | - Marie-Louise Bang
- Institute of Genetic and Biomedical Research, National Research Council of Italy, Milan Unit, Milan, Italy; Humanitas Cardio Center, IRCCS Humanitas Research Hospital, Rozzano (Milan), Italy
| | | | - Christina Brandenberger
- Institute of Functional and Applied Anatomy, Hannover Medical School, Hannover, Germany; Charité-Universitätsmedizin Berlin, Institute of Functional Anatomy, Campus Charité Mitte, Berlin, Germany
| | - Louise Benazzi
- Proteomics and Metabolomic Lab, Institute for Biomedical Technologies, National Research Council, Segrate (Milan), Italy
| | - Dario di Silvestre
- Proteomics and Metabolomic Lab, Institute for Biomedical Technologies, National Research Council, Segrate (Milan), Italy
| | - Antonella de Palma
- Proteomics and Metabolomic Lab, Institute for Biomedical Technologies, National Research Council, Segrate (Milan), Italy
| | - Uwe Primeßnig
- Deutsches Herzzentrum der Charité, Department of Cardiology, Angiology and Intensive Care Medicine, Campus Virchow-Klinikum, Berlin, Germany; Berlin Institute of Health at Charité-Universitätsmedizin Berlin, Berlin, Germany; German Centre for Cardiovascular Research, Berlin, Germany
| | - Felix Hohendanner
- Deutsches Herzzentrum der Charité, Department of Cardiology, Angiology and Intensive Care Medicine, Campus Virchow-Klinikum, Berlin, Germany; Berlin Institute of Health at Charité-Universitätsmedizin Berlin, Berlin, Germany; German Centre for Cardiovascular Research, Berlin, Germany
| | - Simone Perna
- Department of Biology, College of Science, Sakhir Campus, University of Bahrain, Zallaq, Bahrain
| | | | - Paolo Colombo
- Department of Food and Drugs, University of Parma, Parma, Italy; PlumeStars, Parma, Italy
| | - Christian Mühlfeld
- Institute of Functional and Applied Anatomy, Hannover Medical School, Hannover, Germany; Biomedical Research in Endstage and Obstructive Lung Disease Hannover, Member of the German Center for Lung Research, Hannover, Germany
| | - Paul Steendijk
- Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands
| | - Pierluigi Mauri
- Proteomics and Metabolomic Lab, Institute for Biomedical Technologies, National Research Council, Segrate (Milan), Italy
| | - Carsten Tschöpe
- Deutsches Herzzentrum der Charité, Department of Cardiology, Angiology and Intensive Care Medicine, Campus Virchow-Klinikum, Berlin, Germany
| | - Barry Borlaug
- Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA
| | - Burkert M Pieske
- Deutsches Herzzentrum der Charité, Department of Cardiology, Angiology and Intensive Care Medicine, Campus Virchow-Klinikum, Berlin, Germany; Berlin Institute of Health at Charité-Universitätsmedizin Berlin, Berlin, Germany; German Centre for Cardiovascular Research, Berlin, Germany
| | - Philipp Attanasio
- Department of Cardiology, Campus Benjamin Franklin, Charité-Universitätsmedizin, Berlin, Germany
| | - Heiner Post
- Deutsches Herzzentrum der Charité, Department of Cardiology, Angiology and Intensive Care Medicine, Campus Virchow-Klinikum, Berlin, Germany
| | - Frank R Heinzel
- Deutsches Herzzentrum der Charité, Department of Cardiology, Angiology and Intensive Care Medicine, Campus Virchow-Klinikum, Berlin, Germany; German Centre for Cardiovascular Research, Berlin, Germany
| | - Daniele Catalucci
- Institute of Genetic and Biomedical Research, National Research Council of Italy, Milan Unit, Milan, Italy; Humanitas Cardio Center, IRCCS Humanitas Research Hospital, Rozzano (Milan), Italy. https://twitter.com/CNRsocial_
| |
Collapse
|
6
|
Batra J, DeFilippis EM, Clerkin K, Bae D, Oh KT, Lotan D, Topkara VK, Lee SH, Latif F, Colombo P, Yuzefpolskaya M, Raikhelkar J, Majure DT, Sayer G, Uriel N. A change of heart: Characteristics and outcomes of multiple cardiac retransplant recipients. Clin Transplant 2024; 38:e15214. [PMID: 38078705 DOI: 10.1111/ctr.15214] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2023] [Revised: 11/07/2023] [Accepted: 11/17/2023] [Indexed: 01/31/2024]
Abstract
BACKGROUND Among heart transplant (HT) recipients who develop advanced graft dysfunction, cardiac re-transplantation may be considered. A smaller subset of patients will experience failure of their second allograft and undergo repeat re-transplantation. Outcomes among these individuals are not well-described. METHODS Adult and pediatric patients in the United Network for Organ Sharing (UNOS) registry who received HT between January 1, 1990 and December 31, 2020 were included. RESULTS Between 1990 and 2020, 90 individuals received a third HT and three underwent a fourth HT. Recipients were younger than those undergoing primary HT (mean age 32 years). Third HT was associated with significantly higher unadjusted rates of 1-year mortality (18% for third HT vs. 13% for second HT vs. 9% for primary HT, p < .001) and 10-year mortality (59% for third HT vs. 42% for second HT vs. 37% for primary HT, p < .001). Mortality was highest amongst recipients aged >60 years and those re-transplanted for acute graft failure. Long-term rates of CAV, rejection, chronic dialysis, and hospitalization for infection were also higher. CONCLUSIONS Third HT is associated with higher morbidity and mortality than primary HT. Further consensus is needed regarding appropriate organ stewardship for this unique subgroup.
Collapse
Affiliation(s)
- Jaya Batra
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| | - Ersilia M DeFilippis
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| | - Kevin Clerkin
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| | - David Bae
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| | - Kyung Taek Oh
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| | - Dor Lotan
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| | - Veli K Topkara
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| | - Sun Hi Lee
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| | - Farhana Latif
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| | - Paolo Colombo
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| | - Melana Yuzefpolskaya
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| | - Jayant Raikhelkar
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| | - David T Majure
- Division of Cardiology, Department of Medicine, Weill Cornell Medicine, New York, New York, USA
| | - Gabriel Sayer
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| | - Nir Uriel
- Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
| |
Collapse
|
7
|
Turck D, Bohn T, Castenmiller J, De Henauw S, Hirsch‐Ernst KI, Maciuk A, Mangelsdorf I, McArdle HJ, Naska A, Pentieva K, Siani A, Thies F, Tsabouri S, Vinceti M, Aguilera‐Gómez M, Cubadda F, Frenzel T, Heinonen M, Prieto Maradona M, Marchelli R, Neuhäuser‐Berthold M, Peláez C, Poulsen M, Schlatter JR, Siskos A, van Loveren H, Colombo P, Noriega Fernández E, Knutsen HK. Safety of lacto-N-fucopentaose I/2'-fucosyllactose (LNFP-I/2'-FL) mixture as a novel food pursuant to Regulation (EU) 2015/2283. EFSA J 2023; 21:e8412. [PMID: 38046202 PMCID: PMC10691295 DOI: 10.2903/j.efsa.2023.8412] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/05/2023] Open
Abstract
Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on lacto-N-fucopentaose I (LNFP-I)/2'-fucosyllactose (2'-FL) mixture as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF is mainly composed of the human-identical milk oligosaccharides (HiMO) LNFP-I and 2'-FL, but it also contains d-lactose, lacto-N-tetraose, difucosyllactose, 3-fucosyllactose, LNFP-I fructose isomer, 2'-fucosyl-d-lactulose, l-fucose and 2'-fucosyl-d-lactitol, and a small fraction of other related saccharides. The NF is produced by fermentation by a genetically modified strain (Escherichia coli K-12 DH1 MDO MP2173b) of E. coli K-12 DH1 (DSM 4235). The information provided on the identity, manufacturing process, composition and specifications of the NF does not raise safety concerns. The applicant intends to add the NF in a variety of foods, including infant formula (IF) and follow-on formula, foods for infants and toddlers, foods for special medical purposes and food supplements (FS). The target population is the general population. The anticipated daily intake of LNFP-I from use in IF is similar to the estimated natural mean highest daily intake in breastfed infants. Overall, the anticipated daily intake of LNFP-I from the NF as a food ingredient at the maximum proposed use levels is unlikely to exceed the intake level of breastfed infants on a body weight basis. The intake in breastfed infants on a body weight basis is expected to be safe also for other population groups. The anticipated 2'-FL intake is generally rather low. The use of the NF in FS is not intended if other foods with added NF components or human milk (for infants and young children) are consumed on the same day. The Panel concludes that the NF, a mixture of LNFP-I and 2'-FL, is safe under the proposed conditions of use.
Collapse
|
8
|
Turck D, Bohn T, Castenmiller J, De Henauw S, Hirsch‐Ernst KI, Maciuk A, Mangelsdorf I, McArdle HJ, Naska A, Pentieva K, Siani A, Thies F, Tsabouri S, Vinceti M, Aguilera‐Gómez M, Cubadda F, Frenzel T, Heinonen M, Prieto Maradona M, Marchelli R, Neuhäuser‐Berthold M, Peláez C, Poulsen M, Schlatter JR, Siskos A, van Loveren H, Colombo P, Noriega Fernández E, Knutsen HK. Safety of the extension of use of 2'-fucosyllactose (2'-FL) as a novel food pursuant to Regulation (EU) 2015/2283. EFSA J 2023; 21:e08334. [PMID: 37955037 PMCID: PMC10632945 DOI: 10.2903/j.efsa.2023.8334] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2023] Open
Abstract
Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on the safety of the extension of use of 2'-fucosyllactose (2'-FL) as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF is already authorised as ingredient in several food categories, including infant formula (IF) and follow-on formula (FOF). The applicant proposed to increase the maximum use levels of the NF in IF and FOF. EFSA estimated the anticipated daily intake of the NF from the proposed extension of use, including the already authorised conditions of use in other food categories. Additionally, a new intake estimate limited to the already authorised conditions of use of the NF was carried out following EFSA's current approach. The estimated daily intake of the NF from high consumption of IF alone at the proposed maximum use level in infants < 16 weeks of age is similar to the estimated natural highest mean daily intake of 2'-FL from human milk in breastfed infants. The estimated highest P95 daily intakes of the NF from the proposed extension of use in IF and FOF (including the authorised uses in other food categories) and from the already authorised conditions of use, are comparable and both higher than the estimated natural highest mean daily intake of 2'-FL from human milk in infants and to a lesser extent in young children. The Panel considers that the proposed extension of use of the NF in IF and FOF only marginally affects the highest P95 daily intake estimate from the authorised conditions of use, and therefore does not affect the safety of the NF. The Panel concludes that the NF, 2'-FL, is safe under the proposed conditions of use.
Collapse
|
9
|
Turck D, Bohn T, Castenmiller J, De Henauw S, Hirsch‐Ernst KI, Maciuk A, Mangelsdorf I, McArdle HJ, Naska A, Pentieva K, Siani A, Thies F, Tsabouri S, Vinceti M, Aguilera‐Gómez M, Cubadda F, Frenzel T, Heinonen M, Prieto Maradona M, Marchelli R, Neuhäuser‐Berthold M, Peláez C, Poulsen M, Schlatter JR, Siskos A, van Loveren H, Colombo P, Noriega Fernández E, Knutsen HK. Safety of 2'-fucosyllactose (2'-FL) produced by a derivative strain ( Escherichia coli SGR5) of E. coli W (ATCC 9637) as a Novel Food pursuant to Regulation (EU) 2015/2283. EFSA J 2023; 21:e08333. [PMID: 38027450 PMCID: PMC10644224 DOI: 10.2903/j.efsa.2023.8333] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2023] Open
Abstract
Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on 2'-fucosyllactose (2'-FL) as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF is mainly composed of the human-identical milk oligosaccharide (HiMO) 2'-FL, but it also contains d-lactose, l-fucose, fucosylgalactose, difucosyllactose, d-glucose and d-galactose, and a small fraction of other related saccharides. The NF is produced by fermentation by a genetically modified strain (Escherichia coli SGR5) of E. coli W (ATCC 9637). The information provided on the identity, manufacturing process, composition and specifications of the NF does not raise safety concerns. The applicant applies for the same use and use levels as already authorised for 2'-FL and included in the Union list of NFs, with the general population as target population. The Panel noted that the available intake estimate is not recent (2015) and based on a different database (2008-2010 UK data) than that used by EFSA. For this reason, the Panel decided to perform a new intake estimate according to the current EFSA approach. The Panel notes that the highest P95 daily intake of the NF from the use as food ingredient is higher than the estimated natural highest mean daily intake in breastfed infants and marginally higher in young children. The applicant also proposes to extend the use of 2'-FL in food supplements (FS) for infants at the use level of 1.2 g/day. The resulting estimated intake in infants from the proposed use in FS is within the natural intake of 2'-FL in breastfed infants. FS are not intended to be used if other foods with added 2'-FL or human milk are consumed on the same day. The Panel concludes that the NF is safe under the proposed conditions of use.
Collapse
|
10
|
Banella S, Saraswat A, Patel A, Serajuddin ATM, Colombo P, Patel K, Colombo G. In Vitro Assessment of Cisplatin/Hyaluronan Complex for Loco-Regional Chemotherapy. Int J Mol Sci 2023; 24:15725. [PMID: 37958708 PMCID: PMC10647681 DOI: 10.3390/ijms242115725] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2023] [Revised: 09/27/2023] [Accepted: 10/23/2023] [Indexed: 11/15/2023] Open
Abstract
Loco-regional chemotherapy is a strategy used to achieve more precise anticancer drug effect directly on tumor mass, while decreasing whole body exposure, which can lead to undesirable side effects. Thus, the loco-regional chemotherapy is conceptually similar to the targeted drug delivery systems for delivering chemotherapeutics to cancer cells in a certain location of the body. Recently, it has been demonstrated that a novel polymeric film containing the complex between cisplatin (cisPt) and hyaluronan (sodium salt of hyaluronic acid; NaHA) enhanced in vivo efficacy and safety of cisplatin (cisPt) by loco-regional delivery in pleural mesothelioma. Biologically, hyaluronic acid (HA) binds with the CD44 receptor, which is a transmembrane glycoprotein overexpressed by other cancer cells. Thus, administering both cisPt and hyaluronan together as a complex loco-regionally to the tumor site could target cancer cells locally and enhance treatment safety. A slight excess of hyaluronan was required to have more than 85% cisPt complexation. In cell monolayers (2D model) the cisPt/NaHA complex in solution demonstrated dose- and time-dependent cytotoxic effect by decreasing the viability of pancreatic, melanoma, and lung cell lines (they all express CD44). At the same concentration in solution, the complex was as effective as cisPt alone. However, when applied as film to melanoma spheroids (3D model), the complex was superior because it prevented the tumor spheroid growth and, more importantly, the formation of new cell colonies. Hence, cisPt/NaHA complex could work in preventing metastases loco-regionally and potentially avoiding systemic relapses.
Collapse
Affiliation(s)
- Sabrina Banella
- Department of Life Sciences and Biotechnology, University of Ferrara, 44121 Ferrara, Italy; (S.B.); (G.C.)
- College of Pharmacy and Health Sciences, St. John’s University, Queens, NY 11439, USA; (A.S.); (A.P.); (A.T.M.S.)
| | - Aishwarya Saraswat
- College of Pharmacy and Health Sciences, St. John’s University, Queens, NY 11439, USA; (A.S.); (A.P.); (A.T.M.S.)
| | - Akanksha Patel
- College of Pharmacy and Health Sciences, St. John’s University, Queens, NY 11439, USA; (A.S.); (A.P.); (A.T.M.S.)
| | - Abu T. M. Serajuddin
- College of Pharmacy and Health Sciences, St. John’s University, Queens, NY 11439, USA; (A.S.); (A.P.); (A.T.M.S.)
| | | | - Ketan Patel
- College of Pharmacy and Health Sciences, St. John’s University, Queens, NY 11439, USA; (A.S.); (A.P.); (A.T.M.S.)
| | - Gaia Colombo
- Department of Life Sciences and Biotechnology, University of Ferrara, 44121 Ferrara, Italy; (S.B.); (G.C.)
| |
Collapse
|
11
|
Drago G, Ruggieri S, Sprovieri M, Rizzo G, Colombo P, Giosuè C, Quinci E, Traina A, Gastaldelli A, Cibella F, Panunzi S. Exposure profiles in pregnant women from a birth cohort in a highly contaminated area of southern Italy. Sci Rep 2023; 13:14815. [PMID: 37684286 PMCID: PMC10491776 DOI: 10.1038/s41598-023-41865-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2023] [Accepted: 09/01/2023] [Indexed: 09/10/2023] Open
Abstract
Protecting the health of pregnant women from environmental stressors is crucial for reducing the burden of non-communicable diseases. In industrially contaminated sites, this action is particularly challenging due to the heterogeneous pollutant mixtures in environmental matrices. The aim of this study was to evaluate distribution patterns of mercury, hexachlorobenzene and polychlorobiphenyls in the serum of 161 pregnant women recruited in the framework of the Neonatal Environment and Health Outcomes (NEHO) cohort and living both inside and outside the National Priority Contaminated Site (NPCS) of Priolo. Food macro-categories were determined, and serum levels of contaminants were used to perform k-means cluster analysis and identify the role of food in pollutant transfer from the environment. Two groups of mothers with high and low measured pollutant levels were distinguished. Concentrations in mothers in the high-exposure cluster were at least twofold for all the evaluated pollutants (p < 0.0001) and included mothers living inside and outside NPCS, with a predominance of individuals from the NPCS (p = 0.045). Fish consumption was higher in the high-exposure cluster (p = 0.019). These findings suggest a link between contamination of environmental matrices such as sediment with maternal exposure, through the intake of local food. Such consideration appears poorly investigated in the context of contaminated sites.
Collapse
Affiliation(s)
- Gaspare Drago
- Institute for Biomedical Research and Innovation, National Research Council of Italy, Via Ugo La Malfa 153, 90146, Palermo, Italy
| | - Silvia Ruggieri
- Institute for Biomedical Research and Innovation, National Research Council of Italy, Via Ugo La Malfa 153, 90146, Palermo, Italy.
| | - Mario Sprovieri
- Institute of Marine Sciences, National Research Council of Italy, Arsenale-Tesa 104, Castello 2737/F, 30122, Venice, Italy
| | - Giulia Rizzo
- Institute for Biomedical Research and Innovation, National Research Council of Italy, Via Ugo La Malfa 153, 90146, Palermo, Italy
| | - Paolo Colombo
- Institute for Biomedical Research and Innovation, National Research Council of Italy, Via Ugo La Malfa 153, 90146, Palermo, Italy
| | - Cristina Giosuè
- Institute of Anthropic Impacts and Sustainability in Marine Environment, National Research Council of Italy, Lungomare Cristoforo Colombo 4521, 90149, Palermo, Italy
| | - Enza Quinci
- Institute of Anthropic Impacts and Sustainability in Marine Environment, National Research Council of Italy, Via del Mare 3, Torretta Granitola, 91021, Trapani, Italy
| | - Anna Traina
- Institute of Anthropic Impacts and Sustainability in Marine Environment, National Research Council of Italy, Lungomare Cristoforo Colombo 4521, 90149, Palermo, Italy
| | - Amalia Gastaldelli
- Institute of Clinical Physiology, National Research Council of Italy, Via Giuseppe Moruzzi 1, 56124, Pisa, Italy
| | - Fabio Cibella
- Institute for Biomedical Research and Innovation, National Research Council of Italy, Via Ugo La Malfa 153, 90146, Palermo, Italy
| | - Simona Panunzi
- Institute for System Analysis and Computer Science-BioMatLab, National Research Council of Italy, Via dei Taurini 19, 00168, Rome, Italy
| |
Collapse
|
12
|
Turck D, Bohn T, Castenmiller J, De Henauw S, Hirsch‐Ernst KI, Maciuk A, Mangelsdorf I, McArdle HJ, Naska A, Pentieva K, Siani A, Thies F, Tsabouri S, Vinceti M, Aguilera‐Gómez M, Cubadda F, Frenzel T, Heinonen M, Marchelli R, Neuhäuser‐Berthold M, Peláez C, Poulsen M, Prieto Maradona M, Schlatter JR, Siskos A, van Loveren H, Colombo P, Noriega Fernández E, Knutsen HK. Safety of 3'-sialyllactose (3'-SL) sodium salt produced by a derivative strain ( Escherichia coli NEO3) of E. coli W (ATCC 9637) as a Novel Food pursuant to Regulation (EU) 2015/2283. EFSA J 2023; 21:e08224. [PMID: 37746669 PMCID: PMC10512151 DOI: 10.2903/j.efsa.2023.8224] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/26/2023] Open
Abstract
Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on 3'-sialyllactose (3'-SL) sodium salt as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF is mainly composed of the human-identical milk oligosaccharide (HiMO) 3'-SL (sodium salt), but it also contains sialic acid, d-glucose, d-lactose, 3'-sialyllactulose and 6'-sialyllactose sodium salts and a small fraction of other related saccharides. The NF is produced by fermentation by a genetically modified strain (Escherichia coli NEO3) of E. coli W (ATCC 9637). The information provided on the identity, manufacturing process, composition and specifications of the NF does not raise safety concerns. The applicant intends to add the NF to a variety of foods, including infant formula and follow-on formula, food for special medical purposes and food supplements (FS). The target population is the general population. The applicant applies for the same uses and use levels as already assessed for 3'-SL sodium salt produced by a genetically modified strain of E. coli K-12 DH1, with the exception for the use in FS, which is proposed to be higher (from 0.5 to 1.0 g/day) in individuals from 3 years of age. Since the NF as a food ingredient would be consumed at the same extent as the already assessed 3'-SL sodium salt, no new estimates of the intakes have been carried out. The Panel notes that the maximum daily intake of 3'-SL from the proposed use of the NF in FS for individuals from 3 years of age (1.0 g/day) is lower than the estimated highest mean daily intake of 3'-SL in breastfed infants. FS are not intended to be used if other sources of 3'-SL are consumed on the same day. The Panel concludes that the NF is safe under the proposed conditions of use.
Collapse
|
13
|
Shezad N, D'Agostini M, Ezzine A, Franchin G, Colombo P, Akhtar F. 3D-printed zeolite 13X-Strontium chloride units as ammonia carriers. Heliyon 2023; 9:e19376. [PMID: 37810019 PMCID: PMC10558346 DOI: 10.1016/j.heliyon.2023.e19376] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2023] [Revised: 08/21/2023] [Accepted: 08/21/2023] [Indexed: 10/10/2023] Open
Abstract
The selective catalytic reduction (SCR) system in automobiles using urea solution as a source of NH3 suffers from solid deposit problems in pipelines and poor efficiency during engine startup. Although direct use of high pressure NH3 is restricted due to safety concerns, which can be overcome by using solid sorbents as NH3 carrier. Strontium chloride (SrCl2) is considered the best sorbent due to its high sorption capacity; however, challenges are associated with the processing of stable engineering structures due to extraordinary volume expansion during the NH3 sorption. This study reports the fabrication of a novel structure consisting of a zeolite cage enclosing the SrCl2 pellet (SPZC) through extrusion-based 3D printing (Direct Ink Writing). The printed SPZC structure demonstrated steady sorption of NH3 for 10 consecutive cycles without significant uptake capacity and structural integrity loss. Furthermore, the structure exhibited improved sorption and desorption kinetics than pure SrCl2. The synergistic effect of zeolite as physisorbent and SrCl2 as chemisorbent in the novel composite structure enabled the low-pressure (<0.4 bar) and high-pressure (>0.4 bar) NH3 sorption, compared to pure SrCl2, which absorbed NH3 at pressures above 0.4 bar. Regeneration of SPZC composite sorbent under evacuation showed that 87.5% percent of NH3 was desorbed at 20 °C. Thus, the results demonstrate that the rationally designed novel SPZC structure offers safe and efficient storage of NH3 in the SCR system and other applications.
Collapse
Affiliation(s)
- Nasir Shezad
- Division of Materials Science, Department of Engineering Sciences and Mathematics, Luleå University of Technology, Luleå, SE-971 87, Sweden
| | - Marco D'Agostini
- Department of Industrial Engineering, University of Padova, Via Marzolo, 9, Padova, 35131, Italy
| | - Ali Ezzine
- Department of Industrial Engineering, University of Padova, Via Marzolo, 9, Padova, 35131, Italy
| | - Giorgia Franchin
- Department of Industrial Engineering, University of Padova, Via Marzolo, 9, Padova, 35131, Italy
| | - Paolo Colombo
- Department of Industrial Engineering, University of Padova, Via Marzolo, 9, Padova, 35131, Italy
- Department of Materials Science and Engineering, The Pennsylvania State University, University Park, PA, USA
| | - Farid Akhtar
- Division of Materials Science, Department of Engineering Sciences and Mathematics, Luleå University of Technology, Luleå, SE-971 87, Sweden
| |
Collapse
|
14
|
Yao L, Pan L, Zhou S, Liu H, Mei H, Li Y, Dassios KG, Colombo P, Cheng L, Zhang L. Wide-temperature-range multispectral camouflage enabled by orientation-gradient co-optimized microwave blackbody metastructure coupled with conformal MXene coating. Mater Horiz 2023; 10:3404-3415. [PMID: 37350473 DOI: 10.1039/d3mh00611e] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/24/2023]
Abstract
Cloaking against electromagnetic detection is a well-researched topic; yet achieving multispectral camouflage over a wide temperature range remains challenging. Herein, an orientation-gradient co-optimized graded Gyroid-shellular (GGS) SiOC-based metastructure with a conformal MXene coating (M@SiOC) is proposed to achieve wide-temperature-range microwave/infrared/visible-light-compatible camouflage. Firstly, the combination of coordinate transformation and genetic algorithm endows the GGS architecture with optimal orientation and gradient, allowing superior microwave blackbody-like behavior. Secondly, a microwave-transparent, low-infrared-emissivity MXene metasurface is constructed in situ to permit wide-temperature-range infrared camouflage. Finally, the outstanding spectral selectivity of MXene enables camouflage against 1.06 μm-lidar and visible-light detection. As a result, the as-fabricated [110]-oriented GGS M@SiOC metamaterials exhibit outstanding wide-temperature-range multispectral camouflage: (i) ultrabroadband microwave absorption exceeding 80% in the X-Ku band from room temperature (RT) to 500 °C with absorption above 86.0% (91.4% on average) at 500 °C; (ii) excellent long-wavelength infrared camouflage for object temperatures from RT to 450 °C, reaching an infrared signal intensity of 78.5% for objects at 450 °C; and (iii) camouflage against both 1.06 μm-lidar and dark environment. Compared with traditional hierarchical metamaterials necessitating complex micro/nano-fabrication processes, this work provides a novel pathway toward the realization of structurally integrated multispectral stealth components by combining flexible metastructure design and high-fidelity additive manufacturing.
Collapse
Affiliation(s)
- Li Yao
- Science and technology on Thermostructural Composite Materials Laboratory, School of Materials Science and Engineering, Northwestern Polytechnical University, Xi'an Shaanxi 710072, P. R. China.
| | - Longkai Pan
- Science and technology on Thermostructural Composite Materials Laboratory, School of Materials Science and Engineering, Northwestern Polytechnical University, Xi'an Shaanxi 710072, P. R. China.
| | - Shixiang Zhou
- Science and technology on Thermostructural Composite Materials Laboratory, School of Materials Science and Engineering, Northwestern Polytechnical University, Xi'an Shaanxi 710072, P. R. China.
- Department of Materials Science and Engineering, National University of Singapore, 9 Engineering Drive 1, Singapore 117576, Singapore
| | - Hongxia Liu
- Science and technology on Thermostructural Composite Materials Laboratory, School of Materials Science and Engineering, Northwestern Polytechnical University, Xi'an Shaanxi 710072, P. R. China.
| | - Hui Mei
- Science and technology on Thermostructural Composite Materials Laboratory, School of Materials Science and Engineering, Northwestern Polytechnical University, Xi'an Shaanxi 710072, P. R. China.
| | - Yang Li
- National Key Laboratory of Science and Technology on High-strength Structural Materials, Central South University, Changsha 410083, China
| | - Konstantinos G Dassios
- Department of Chemical Engineering, University of Patras, Karatheodory 1, Patras 26504, Greece
| | - Paolo Colombo
- Department of Industrial Engineering, University of Padova, Padova 35131, Italy
- Department of Materials Science and Engineering, The Pennsylvania State University, University Park, PA 16802, USA
| | - Laifei Cheng
- Science and technology on Thermostructural Composite Materials Laboratory, School of Materials Science and Engineering, Northwestern Polytechnical University, Xi'an Shaanxi 710072, P. R. China.
| | - Litong Zhang
- Science and technology on Thermostructural Composite Materials Laboratory, School of Materials Science and Engineering, Northwestern Polytechnical University, Xi'an Shaanxi 710072, P. R. China.
| |
Collapse
|
15
|
Vinogradsky AV, Hayashi H, Kirschner M, Ning Y, Kurlansky P, Yuzefpolskaya M, Colombo P, Sayer G, Uriel N, Naka Y, Takeda K. Preoperative Left Ventricular Diastolic Dimension Index Is Associated With Outcomes After HeartMate 3 Implantation. Eur J Cardiothorac Surg 2023:ezad287. [PMID: 37589647 DOI: 10.1093/ejcts/ezad287] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/03/2023] [Revised: 07/04/2023] [Accepted: 08/16/2023] [Indexed: 08/18/2023] Open
Abstract
OBJECTIVE We investigated the association between indexed left ventricular diastolic dimension and clinical outcomes after HeartMate 3 implantation. METHODS We retrospectively reviewed patients implanted with the HeartMate 3 at our center between November 2014 and September 2021. Left ventricular diastolic dimension was assessed via preoperative transthoracic echocardiography and left ventricular diastolic dimension index was calculated as left ventricular diastolic dimension/body surface area. The primary outcome was a composite of death or readmission due to right heart failure or stroke. The cut-off left ventricular diastolic dimension index value most closely associated with outcomes was determined by receiver-operating characteristic curve and restricted cubic spline analyses. RESULTS Left ventricular diastolic dimension index measurements were available for 252 of 253 (99.6%) patients. Using a left ventricular diastolic dimension index cut-off value of 33.5 mm/m2, the cohort was divided: left ventricular diastolic dimension index ≤ (n = 131) or > (n=121) 33.5 mm/m2. While there were no significant differences in age, INTERMACS level, and preoperative hemodynamics between groups, patients with smaller left ventricular diastolic dimension index were more likely to have a larger body surface area (2.1 vs 1.9 m2, P<0.001), ischemic cardiomyopathy (64 [49%] vs 40 [33%], P=0.01), and smaller left atrium volume index (40.5 [32.3-54.0] mL/m2 vs. 54.0 [43.0-66.8] mL/m2, P<0.001). Smaller left ventricular diastolic dimension index patients had significantly worse survival (74% vs 88%, log-rank P=0.009) and freedom from adverse events (55% vs 73%, log-rank P=0.005) at 3-year follow-up. Smaller left ventricular diastolic dimension index was independently associated with the composite outcome (Hazard ratio 2.24, P=0.002). CONCLUSIONS Smaller preoperative left ventricular diastolic dimension index is associated with worse outcomes in patients undergoing HeartMate 3 implantation.
Collapse
Affiliation(s)
- Alice V Vinogradsky
- Division of Cardiac, Thoracic & Vascular Surgery, Department of Surgery, Columbia University Irving Medical Center, New York, NY, USA
| | - Hideyuki Hayashi
- Division of Cardiac, Thoracic & Vascular Surgery, Department of Surgery, Columbia University Irving Medical Center, New York, NY, USA
| | - Michael Kirschner
- Division of Cardiac, Thoracic & Vascular Surgery, Department of Surgery, Columbia University Irving Medical Center, New York, NY, USA
| | - Yuming Ning
- Center for Innovation and Outcomes Research, Department of Surgery, Columbia University Irving Medical Center, New York, NY, USA
| | - Paul Kurlansky
- Center for Innovation and Outcomes Research, Department of Surgery, Columbia University Irving Medical Center, New York, NY, USA
- Division of Cardiac, Thoracic & Vascular Surgery, Department of Surgery, Columbia University Irving Medical Center, New York, NY, USA
| | - Melana Yuzefpolskaya
- Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA
| | - Paolo Colombo
- Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA
| | - Gabriel Sayer
- Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA
| | - Nir Uriel
- Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA
| | - Yoshifumi Naka
- Division of Cardiac, Thoracic & Vascular Surgery, Department of Surgery, Columbia University Irving Medical Center, New York, NY, USA
| | - Koji Takeda
- Division of Cardiac, Thoracic & Vascular Surgery, Department of Surgery, Columbia University Irving Medical Center, New York, NY, USA
| |
Collapse
|
16
|
Liu X, Liu H, Wu H, Zhou Q, Liang H, Liu G, Duan W, Gu Y, Xu C, Travitzky N, Colombo P, Riedel R. Structural Electromagnetic Absorber Based on MoS 2 /PyC-Al 2 O 3 Ceramic Metamaterials. Small 2023; 19:e2300664. [PMID: 37086106 DOI: 10.1002/smll.202300664] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/13/2023] [Revised: 04/03/2023] [Indexed: 05/03/2023]
Abstract
Limited by the types of suitable absorbents as well as the challenges in engineering the nanostructures (e.g., defects, dipoles, and hetero-interface) using state-of-the-art additive manufacturing (AM) techniques, the electromagnetic (EM) wave absorption performance of the current ceramic-based materials is still not satisfying. Moreover, because of the high residual porosity and the possible formation of cracks during sintering or pyrolysis, AM-formed ceramic components may in many cases exhibit low mechanical strength. In this work, semiconductive MoS2 and conductive PyC modified Al2 O3 (MoS2 /PyC-Al2 O3 ) ceramic-based structural EM metamaterials are developed by innovatively harnessing AM, precursor infiltration and pyrolysis (PIP), and hydrothermal methods. Three different meta-structures are successfully created, and the ceramic-based nanocomposite benefit from its optimization of EM parameters. Ultra-broad effective absorption bandwidth (EAB) of 35 GHz is achieved by establishment of multi-loss mechanism via nanostructure engineering and fabrication of meta-structures via AM. Due to the strengthening by the PyC phase, the bending strength of the resulting ceramics can reach ≈327 MPa, which is the highest value measured on 3D-printed ceramics of this type that has been reported so far. For the first time, the positive effect deriving from the engineering of the microscopic nano/microstructure and of the macroscopic meta-structure of the absorber on the permittivity and EM absorption performance is proposed. Integration of outstanding mechanical strength and ultra-broad EAB is innovatively realized through a multi-scale design route. This work provides new insights for the design of advanced ceramic-based metamaterials with outstanding performance under extreme environment.
Collapse
Affiliation(s)
- Xingmin Liu
- State Key Laboratory of Solidification Processing, Northwestern Polytechnical University, Xi'an, 710072, China
- Institute of Materials Science, Technische Universität Darmstadt, Alarich-Weiss-Str. 2, 64287, Darmstadt, Germany
| | - Heqiang Liu
- State Key Laboratory of Solidification Processing, Northwestern Polytechnical University, Xi'an, 710072, China
| | - Hongjing Wu
- MOE Key Laboratory of Material Physics and Chemistry under Extraordinary, School of Physical Science and Technology, Northwestern Polytechnical University, Xi'an, 710072, P. R. China
| | - Qian Zhou
- School of Science, Xi'an University of Posts and Telecommunications, Xi'an, 710121, China
| | - Hongsheng Liang
- MOE Key Laboratory of Material Physics and Chemistry under Extraordinary, School of Physical Science and Technology, Northwestern Polytechnical University, Xi'an, 710072, P. R. China
| | - Guoqiang Liu
- State Key Laboratory of Solidification Processing, Northwestern Polytechnical University, Xi'an, 710072, China
| | - Wenyan Duan
- Key Laboratory of Space Manufacturing Technology (SMT), Technology and Engineering Centre of Space Utilization, Chinese Academy of Sciences, Beijing, 100094, P R China
| | - Yue Gu
- Key Laboratory of Space Manufacturing Technology (SMT), Technology and Engineering Centre of Space Utilization, Chinese Academy of Sciences, Beijing, 100094, P R China
| | - Chengying Xu
- Department of Mechanical and Aerospace Engineering, NC State University, Raleigh, NC, 27607, USA
| | - Nahum Travitzky
- Department of Materials Science, Glass and Ceramics, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054, Erlangen, Germany
| | - Paolo Colombo
- Department of Industrial Engineering, University of Padova, Padova, 35131, Italy
| | - Ralf Riedel
- State Key Laboratory of Solidification Processing, Northwestern Polytechnical University, Xi'an, 710072, China
- Institute of Materials Science, Technische Universität Darmstadt, Alarich-Weiss-Str. 2, 64287, Darmstadt, Germany
| |
Collapse
|
17
|
Colombo P, Franchin G. Improving glass nanostructure fabrication. Science 2023; 380:895-896. [PMID: 37262160 DOI: 10.1126/science.adi2747] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
A new method offers high-resolution three-dimensional printing and low-temperature firing.
Collapse
Affiliation(s)
- Paolo Colombo
- Department of Industrial Engineering, University of Padova, Padova, Italy
- Department of Materials Science and Engineering, The Pennsylvania State University, University Park, PA, USA
| | - Giorgia Franchin
- Department of Industrial Engineering, University of Padova, Padova, Italy
| |
Collapse
|
18
|
Turck D, Bohn T, Castenmiller J, De Henauw S, Hirsch‐Ernst KI, Maciuk A, Mangelsdorf I, McArdle HJ, Naska A, Pelaez C, Pentieva K, Siani A, Thies F, Tsabouri S, Vinceti M, Aguilera‐Gómez M, Cubadda F, Frenzel T, Heinonen M, Prieto Maradona M, Marchelli R, Neuhäuser‐Berthold M, Poulsen M, Schlatter JR, Siskos A, van Loveren H, Colombo P, Noriega Fernández E, Knutsen HK. Safety of 6'-sialyllactose (6'-SL) sodium salt produced by a derivative strain ( Escherichia coli NEO6) of E. coli W (ATCC 9637) as a Novel Food pursuant to Regulation (EU) 2015/2283. EFSA J 2023; 21:e08025. [PMID: 37313319 PMCID: PMC10258722 DOI: 10.2903/j.efsa.2023.8025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/15/2023] Open
Abstract
Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on 6'-sialyllactose (6'-SL) sodium salt as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF is mainly composed of the human-identical milk oligosaccharide (HiMO) 6'-SL (sodium salt), but it also contains sialic acid, d-glucose, d-lactose, 6'-sialyllactulose sodium salt, 3'-sialyllactose (3'-SL) sodium salt and a small fraction of other related saccharides. The NF is produced by fermentation by a genetically modified strain (Escherichia coli NEO6) of E. coli W (ATCC 9637). The information provided on the identity, manufacturing process, composition and specifications of the NF does not raise safety concerns. The applicant intends to add the NF to a variety of foods, including infant formula and follow-on formula, food for special medical purposes and food supplements (FS). The target population is the general population. The applicant applies for the same uses and use levels already assessed for 6'-SL sodium salt produced by fermentation by a genetically modified strain of E. coli K-12 DH1. Therefore, since the NF would be consumed at the same extent as the already assessed 6'-SL sodium salt, no new estimates of the intake have been carried out. Similarly, FS are not intended to be used if other foods with added 6'-SL or human milk are consumed on the same day. The Panel concludes that the NF is safe under the proposed conditions of use.
Collapse
|
19
|
Turck D, Bohn T, Castenmiller J, De Henauw S, Hirsch‐Ernst KI, Maciuk A, Mangelsdorf I, McArdle HJ, Naska A, Pelaez C, Pentieva K, Siani A, Thies F, Tsabouri S, Vinceti M, Aguilera‐Gómez M, Cubadda F, Frenzel T, Heinonen M, Prieto Maradona M, Marchelli R, Neuhäuser‐Berthold M, Poulsen M, Schlatter JR, Siskos A, van Loveren H, Colombo P, Noriega Fernández E, Knutsen HK. Safety of 3-fucosyllactose (3-FL) produced by a derivative strain of Escherichia coli K-12 DH1 as a novel food pursuant to Regulation (EU) 2015/2283. EFSA J 2023; 21:e08026. [PMID: 37304347 PMCID: PMC10248826 DOI: 10.2903/j.efsa.2023.8026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/13/2023] Open
Abstract
Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on 3-fucosyllactose (3-FL) as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF is mainly composed of the human-identical milk oligosaccharide (HiMO) 3-FL, but it also contains d-lactose, l-fucose, 3-fucosyllactulose and a small fraction of other related saccharides. The NF is produced by fermentation by a genetically modified strain (Escherichia coli K-12 DH1 MDO MAP1834) of E. coli K-12 DH1 (DSM 4235). The information provided on the manufacturing process, composition and specifications of the NF does not raise safety concerns. The applicant intends to add the NF to a variety of foods, including infant formula and follow-on formula, food for special medical purposes and food supplements (FS). The target population is the general population. The anticipated daily intake of 3-FL from both proposed and combined (authorised and proposed) uses at their respective maximum use levels in all population categories does not exceed the highest intake level of 3-FL from human milk in infants on a body weight basis. The intake of 3-FL in breastfed infants on a body weight basis is expected to be safe also for other population groups. The intake of other carbohydrate-type compounds structurally related to 3-FL is also considered of no safety concern. FS are not intended to be used if other foods with added 3-FL or human milk are consumed on the same day. The Panel concludes that the NF is safe under the proposed conditions of use.
Collapse
|
20
|
DeFilippis E, Oren D, Lotan D, Harris E, Clerkin K, Fried J, Raikhelkar J, Yuzefpolskaya M, Colombo P, Lin E, Oh K, Latif F, Uriel N, Sayer G. Comparison of Two Commercially Available Donor-Derived Cell-Free DNA Assays for Surveillance of Rejection in Heart Transplant Recipients. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.1584] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
21
|
Batra J, Topkara V, Clerkin K, Latif F, Fried J, Raikhelkar J, Lotan D, Donald E, Lumish H, Oh K, Yuzefpolskaya M, Colombo P, Lin E, Sayer G, Uriel N. Multi-Organ Transplantation in Hiv-Positive Recipients - Patient Characteristics and Outcomes. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.555] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
22
|
Lotan D, Park R, Rubinstein G, Moeller C, DeFilippis E, Oh K, Slomovich S, Oren D, Lin E, Clerkin K, Latif F, Colombo P, Yuzefpolskaya M, Topkara V, Kim J, Majure D, Sayer G, Jonathan W, Uriel N. The Utility and Characteristics of Cardiovascular Magnetic Resonance Imaging in Suspected Chronic Allograft Rejection. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.509] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
23
|
Moeller C, Rubinstein G, Lotan D, Oren D, Clerkin K, Raikhelkar J, Colombo P, Leahy N, Fried J, Takeda K, Naka Y, Topkara V, Yuzefpolskaya M, Sayer G, Uriel N. Validation of the Heartmate 3 Survival Risk Score in a Large Left Ventricular Assist Device Center. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.807] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
24
|
Rubinstein G, Lotan D, Moeller C, Slomovich S, Oren D, Fried J, Clerkin K, Topkara V, Raikhelkar J, Oh K, Takeda K, Naka Y, Kaku Y, Colombo P, Yuzefpolskaya M, Latif F, Sayer G, Uriel N. The Hemodynamic Effects of Pump Speed Adjustments in Patients with Heartmate 3 Left Ventricular Assist Device. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.1271] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
25
|
Sewanan L, Harris E, Topkara V, Fried J, Raikhelkar J, Colombo P, Sayer G, Castillo M, Lam E, Chernovolenko M, Yuzefpolskaya M, DeFilippis E, Latif F, Takeda K, Johnson L, Uriel N, Einstein A, Clerkin K. Visually Estimated Coronary Artery Calcium is an Independent Prognostic Marker Following Heart Transplantation. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.169] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
26
|
Kirschner M, Topkara V, Ning Y, Kurlansky P, Kaku Y, Naka Y, Shih H, Yuzefpolskaya M, Colombo P, Sayer G, Uriel N, Takeda K. Comparing Long-Term Survival and Readmissions Between Heartmate 3 and Heart Transplant as Primary Treatment for Advanced Heart Failure. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
27
|
Mehlman Y, Lotan D, Rubinstein G, Moeller C, Oren D, Slomovich S, Latif F, Lee S, Oh K, Lin E, Raikhelkar J, Clerkin K, Fried J, Yuzefpolskaya M, DeFilippis E, Colombo P, Topkara V, Lewis M, Sayer G, Axsom K, Uriel N. Donor-Derived Cell-Free DNA in Heart Transplant Recipients with a History of Congenital Heart Disease. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.1240] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
28
|
Latif F, Sayer G, Lotan D, Mendoza J, Regan M, Tsapepas D, Ramakrishnan A, DeFilippis E, Yuzefpolskaya M, Colombo P, Kennel P, Raikhelkar J, Clerkin K, Fried J, Lin E, Lee S, Naka Y, Takeda K, Uriel N. The Effect of Temperature Control Versus Icebox Preservation on Post Heart Transplant Outcome. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.498] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
29
|
Lotan D, Rubinstein G, Moeller C, Slomovich S, Oren D, DeFilippis E, Raikhelkar J, Clerkin K, Fried J, Majure D, Naka Y, Kaku Y, Takeda K, Oh K, Lin E, Lee S, Topkara V, Colombo P, Yuzefpolskaya M, Latif F, Sayer G, Uriel N, Miroslav S. The Effect of Preservation Modality on Myocardial Injury - A Single Blinded Study. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.1534] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
30
|
Concha D, Chung A, Lumish H, Batra J, Sayer G, Clerkin K, Raikhelkar J, Colombo P, Naka Y, Latif F, Takeda K, Fried J, Yuzefpolskaya M, Kaku Y, Uriel N. Actual-to-Expected Advanced Heart Failure Therapy Utilization in the United States by Race/Ethnicity. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.532] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
31
|
Rubinstein G, Lotan D, Moeller C, Slomovich S, Oren D, Mehlman Y, DeFilippis E, Lin E, Raikhelkar J, Clerkin K, Donald E, Oh K, Kleet A, Majure D, Lee S, Topkara V, Colombo P, Latif F, Yuzefpolskaya M, Sayer G, Uriel N. Donor-Derived Cell-Free DNA in Heart Transplant Recipients Bridged with Left Ventricular Assist Device. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.577] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
32
|
Harris E, Sewanan L, Topkara V, Fried J, Raikhelkar J, Colombo P, Yuzefpolskaya M, DeFilippis E, Latif F, Castillo M, Lam E, Takeda K, Chernovolenko M, Einstein A, Johnson L, Uriel N, Sayer G, Clerkin K. Isolated Microvascular Cardiac Allograft Vasculopathy is Associated with an Increased Risk of Death or Retransplantation. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.1576] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
33
|
Harris E, Sewanan L, Topkara V, Fried J, Raikhelkar J, Colombo P, Yuzefpolskaya M, DeFilippis E, Latif F, Takeda K, Hassanein M, Singh S, Sayer G, Uriel N, Clerkin K. New System, Familiar Problem: Increased Wait Time for High Priority Heart Transplant Candidates. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.1665] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
34
|
Lotan D, Moeller C, Rubinstein G, Oren D, Mehlman Y, Slomovich S, Aishwarya R, DeFilippis E, Fried J, Clerkin K, Raikhelkar J, Oh K, Lin E, Lee S, Colombo P, Kleet A, Yuzefpolskaya M, Topkara V, Latif F, Sayer G, Uriel N. Persistently Elevated Donor-Derived Cell-Free DNA in Heart Transplant Recipients. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.578] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
35
|
Batra J, Rosenblum H, DeFilippis E, Donald E, Clerkin K, Topkara V, Lee S, Latif F, Yuzefpolskaya M, Colombo P, Oh K, Lotan D, Raikhelkar J, Sayer G, Uriel N. Characteristics and Outcomes of Multiple Cardiac Re-Transplant Recipients. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.191] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
36
|
Quarta E, Chiappi M, Adamiano A, Tampieri A, Wang W, Tetley TD, Buttini F, Sonvico F, Catalucci D, Colombo P, Iafisco M, Degli Esposti L. Inhalable Microparticles Embedding Biocompatible Magnetic Iron-Doped Hydroxyapatite Nanoparticles. J Funct Biomater 2023; 14:jfb14040189. [PMID: 37103279 PMCID: PMC10145219 DOI: 10.3390/jfb14040189] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2023] [Revised: 03/21/2023] [Accepted: 03/27/2023] [Indexed: 03/31/2023] Open
Abstract
Recently, there has been increasing interest in developing biocompatible inhalable nanoparticle formulations, as they have enormous potential for treating and diagnosing lung disease. In this respect, here, we have studied superparamagnetic iron-doped calcium phosphate (in the form of hydroxyapatite) nanoparticles (FeCaP NPs) which were previously proved to be excellent materials for magnetic resonance imaging, drug delivery and hyperthermia-related applications. We have established that FeCaP NPs are not cytotoxic towards human lung alveolar epithelial type 1 (AT1) cells even at high doses, thus proving their safety for inhalation administration. Then, D-mannitol spray-dried microparticles embedding FeCaP NPs have been formulated, obtaining respirable dry powders. These microparticles were designed to achieve the best aerodynamic particle size distribution which is a critical condition for successful inhalation and deposition. The nanoparticle-in-microparticle approach resulted in the protection of FeCaP NPs, allowing their release upon microparticle dissolution, with dimensions and surface charge close to the original values. This work demonstrates the use of spray drying to provide an inhalable dry powder platform for the lung delivery of safe FeCaP NPs for magnetically driven applications.
Collapse
|
37
|
Ma S, Yang H, Fu S, He P, Duan X, Yang Z, Jia D, Colombo P, Zhou Y. Additive manufacturing of geopolymers with hierarchical porosity for highly efficient removal of Cs . J Hazard Mater 2023; 443:130161. [PMID: 36327833 DOI: 10.1016/j.jhazmat.2022.130161] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/08/2022] [Revised: 09/26/2022] [Accepted: 10/07/2022] [Indexed: 06/16/2023]
Abstract
Geopolymers (GPs) have emerged as promising adsorbents for wastewater treatment due to their superior adsorption stability, tunable porosity, high adsorption capacity, and low-energy production. Despite their great promise, developing GPs with well-controlled hierarchical structures and high porosity remains challenging, and the mechanism underlying the ion adsorption process remains elusive. Here we report a cost-effective and universal approach to fabricate Na or K GPs with sophisticated architectures, high porosity, and arbitrary cation species exchange by means of additive manufacturing and a surfactant. The introduction of sodium lauryl sulfate (SLS) enhanced the porosity of the GP adsorbents, yielding NaGP-lattice-10%SLS adsorbent with a high total porosity of 80.8 vol%. Combining static and dynamic adsorption tests, the effects of morphology, surfactant content, and cation species on Cs+ adsorption performance were systemically investigated. With an initial Cs+ concentration of 900 mg/L, the printed NaGP exhibited a maximum Cs+ adsorption capacity of 80.1 mg/g, outperforming other adsorbents reported so far. The quasi-second-order fit of the NaGP adsorbent showed overall higher R2 values than the quasi-first-order fit, indicating that the adsorption process was dominated by ion exchange. Combined with first-principles calculations, we verified that the content of water in the GP sod cages also affected the ion-exchange process between Na+ and Cs+.
Collapse
Affiliation(s)
- Siqi Ma
- Institute for Advanced Ceramics, School of Materials Science and Engineering, Harbin Institute of Technology, Harbin, China; Key Laboratory of Advanced Structural-Functional Integration Materials & Green Manufacturing Technology, Harbin Institute of Technology, Harbin, China
| | - Hualong Yang
- Institute for Advanced Ceramics, School of Materials Science and Engineering, Harbin Institute of Technology, Harbin, China; Key Laboratory of Advanced Structural-Functional Integration Materials & Green Manufacturing Technology, Harbin Institute of Technology, Harbin, China
| | - Shuai Fu
- Max Planck Institute for Polymer Research, Mainz, Germany
| | - Peigang He
- Institute for Advanced Ceramics, School of Materials Science and Engineering, Harbin Institute of Technology, Harbin, China; Key Laboratory of Advanced Structural-Functional Integration Materials & Green Manufacturing Technology, Harbin Institute of Technology, Harbin, China.
| | - Xiaoming Duan
- Institute for Advanced Ceramics, School of Materials Science and Engineering, Harbin Institute of Technology, Harbin, China; Key Laboratory of Advanced Structural-Functional Integration Materials & Green Manufacturing Technology, Harbin Institute of Technology, Harbin, China
| | - Zhihua Yang
- Institute for Advanced Ceramics, School of Materials Science and Engineering, Harbin Institute of Technology, Harbin, China; Key Laboratory of Advanced Structural-Functional Integration Materials & Green Manufacturing Technology, Harbin Institute of Technology, Harbin, China
| | - Dechang Jia
- Institute for Advanced Ceramics, School of Materials Science and Engineering, Harbin Institute of Technology, Harbin, China; Key Laboratory of Advanced Structural-Functional Integration Materials & Green Manufacturing Technology, Harbin Institute of Technology, Harbin, China.
| | - Paolo Colombo
- Department of Industrial Engineering, University of Padova, Padova, Italy; Department of Materials Science and Engineering, The Pennsylvania State University, Philadelphia, USA
| | - Yu Zhou
- Institute for Advanced Ceramics, School of Materials Science and Engineering, Harbin Institute of Technology, Harbin, China; Key Laboratory of Advanced Structural-Functional Integration Materials & Green Manufacturing Technology, Harbin Institute of Technology, Harbin, China
| |
Collapse
|
38
|
Pandini M, Carriero R, Buffi N, Carvetta M, Iovino M, Casale P, Lughezzani G, Hurle R, Alberto S, Fasulo V, Guazzoni G, Elefante G, Colombo P, Basso G, Marchini S, Kunderfranco P, Di Mitri D, Lazzeri M. Single cell-based immune profiling of the tumor and its immune microenvironment revealed differences between non-muscle invasive and muscle invasive bladder cancer. Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)00474-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
39
|
Romano M, González Gómez MA, Santonicola P, Aloi N, Offer S, Pantzke J, Raccosta S, Longo V, Surpi A, Alacqua S, Zampi G, Dediu VA, Michalke B, Zimmerman R, Manno M, Piñeiro Y, Colombo P, Di Schiavi E, Rivas J, Bergese P, Di Bucchianico S. Synthesis and Characterization of a Biocompatible Nanoplatform Based on Silica-Embedded SPIONs Functionalized with Polydopamine. ACS Biomater Sci Eng 2023; 9:303-317. [PMID: 36490313 DOI: 10.1021/acsbiomaterials.2c00946] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Superparamagnetic iron oxide nanoparticles (SPIONs) have gained increasing interest in nanomedicine, but most of those that have entered the clinical trials have been withdrawn due to toxicity concerns. Therefore, there is an urgent need to design low-risk and biocompatible SPION formulations. In this work, we present an original safe-by-design nanoplatform made of silica nanoparticles loaded with SPIONs and decorated with polydopamine (SPIONs@SiO2-PDA) and the study of its biocompatibility performance by an ad hoc thorough in vitro to in vivo nanotoxicological methodology. The results indicate that the SPIONs@SiO2-PDA have excellent colloidal stability in serum-supplemented culture media, even after long-term (24 h) exposure, showing no cytotoxic or genotoxic effects in vitro and ex vivo. Physiological responses, evaluated in vivo using Caenorhabditis elegans as the animal model, showed no impact on fertility and embryonic viability, induction of an oxidative stress response, and a mild impact on animal locomotion. These tests indicate that the synergistic combination of the silica matrix and PDA coating we developed effectively protects the SPIONs, providing enhanced colloidal stability and excellent biocompatibility.
Collapse
Affiliation(s)
- Miriam Romano
- Department of Molecular and Translational Medicine, University of Brescia, Brescia25123, Italy.,Center for Colloid and Surface Science (CSGI), Florence50019, Italy.,Joint Mass Spectrometry Center (JMSC) at Comprehensive Molecular Analytics, Helmholtz Zentrum München, Neuherberg85764, Germany
| | - Manuel Antonio González Gómez
- NANOMAG Laboratory, Applied Physics Department, iMATUS Materials Institute, Universidade de Santiago de Compostela, Santiago de Compostela15782, Spain
| | - Pamela Santonicola
- Institute of Biosciences and BioResources (IBBR), National Research Council of Italy (CNR), Naples80131, Italy
| | - Noemi Aloi
- Institute for Biomedical Research and Innovation (IRIB), National Research Council of Italy (CNR), Palermo90146, Italy
| | - Svenja Offer
- Joint Mass Spectrometry Center (JMSC) at Comprehensive Molecular Analytics, Helmholtz Zentrum München, Neuherberg85764, Germany
| | - Jana Pantzke
- Joint Mass Spectrometry Center (JMSC) at Comprehensive Molecular Analytics, Helmholtz Zentrum München, Neuherberg85764, Germany
| | - Samuele Raccosta
- Institute of Biophysics (IBF), National Research Council of Italy (CNR), Palermo90146, Italy
| | - Valeria Longo
- Institute for Biomedical Research and Innovation (IRIB), National Research Council of Italy (CNR), Palermo90146, Italy
| | - Alessandro Surpi
- Institute of Nanostructured Materials (ISMN), National Research Council of Italy (CNR), Bologna40129, Italy
| | - Silvia Alacqua
- Department of Molecular and Translational Medicine, University of Brescia, Brescia25123, Italy.,Center for Colloid and Surface Science (CSGI), Florence50019, Italy.,Joint Mass Spectrometry Center (JMSC) at Comprehensive Molecular Analytics, Helmholtz Zentrum München, Neuherberg85764, Germany
| | - Giuseppina Zampi
- Institute of Biosciences and BioResources (IBBR), National Research Council of Italy (CNR), Naples80131, Italy
| | - Valentin Alek Dediu
- Institute of Nanostructured Materials (ISMN), National Research Council of Italy (CNR), Bologna40129, Italy
| | - Bernhard Michalke
- Research Unit Analytical BioGeoChemistry, Helmholtz Zentrum München, Neuherberg85764, Germany
| | - Ralf Zimmerman
- Joint Mass Spectrometry Center (JMSC) at Comprehensive Molecular Analytics, Helmholtz Zentrum München, Neuherberg85764, Germany
| | - Mauro Manno
- Institute of Biophysics (IBF), National Research Council of Italy (CNR), Palermo90146, Italy
| | - Yolanda Piñeiro
- NANOMAG Laboratory, Applied Physics Department, iMATUS Materials Institute, Universidade de Santiago de Compostela, Santiago de Compostela15782, Spain
| | - Paolo Colombo
- Institute for Biomedical Research and Innovation (IRIB), National Research Council of Italy (CNR), Palermo90146, Italy
| | - Elia Di Schiavi
- Institute of Biosciences and BioResources (IBBR), National Research Council of Italy (CNR), Naples80131, Italy
| | - José Rivas
- NANOMAG Laboratory, Applied Physics Department, iMATUS Materials Institute, Universidade de Santiago de Compostela, Santiago de Compostela15782, Spain
| | - Paolo Bergese
- Department of Molecular and Translational Medicine, University of Brescia, Brescia25123, Italy.,Center for Colloid and Surface Science (CSGI), Florence50019, Italy
| | - Sebastiano Di Bucchianico
- Joint Mass Spectrometry Center (JMSC) at Comprehensive Molecular Analytics, Helmholtz Zentrum München, Neuherberg85764, Germany
| |
Collapse
|
40
|
Longo V, Aloi N, Lo Presti E, Fiannaca A, Longo A, Adamo G, Urso A, Meraviglia S, Bongiovanni A, Cibella F, Colombo P. Impact of the flame retardant 2,2'4,4'-tetrabromodiphenyl ether (PBDE-47) in THP-1 macrophage-like cell function via small extracellular vesicles. Front Immunol 2023; 13:1069207. [PMID: 36685495 PMCID: PMC9852912 DOI: 10.3389/fimmu.2022.1069207] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2022] [Accepted: 12/13/2022] [Indexed: 01/07/2023] Open
Abstract
2,2'4,4'-tetrabromodiphenyl ether (PBDE-47) is one of the most widespread environmental brominated flame-retardant congeners which has also been detected in animal and human tissues. Several studies have reported the effects of PBDEs on different health issues, including neurobehavioral and developmental disorders, reproductive health, and alterations of thyroid function. Much less is known about its immunotoxicity. The aim of our study was to investigate the effects that treatment of THP-1 macrophage-like cells with PBDE-47 could have on the content of small extracellular vesicles' (sEVs) microRNA (miRNA) cargo and their downstream effects on bystander macrophages. To achieve this, we purified sEVs from PBDE-47 treated M(LPS) THP-1 macrophage-like cells (sEVsPBDE+LPS) by means of ultra-centrifugation and characterized their miRNA cargo by microarray analysis detecting the modulation of 18 miRNAs. Furthermore, resting THP-1 derived M(0) macrophage-like cells were cultured with sEVsPBDE+LPS, showing that the treatment reshaped the miRNA profiles of 12 intracellular miRNAs. This dataset was studied in silico, identifying the biological pathways affected by these target genes. This analysis identified 12 pathways all involved in the maturation and polarization of macrophages. Therefore, to evaluate whether sEVsPBDE+LPS can have some immunomodulatory activity, naïve M(0) THP-1 macrophage-like cells cultured with purified sEVsPBDE+LPS were studied for IL-6, TNF-α and TGF-β mRNAs expression and immune stained with the HLA-DR, CD80, CCR7, CD38 and CD209 antigens and analyzed by flow cytometry. This analysis showed that the PBDE-47 treatment does not induce the expression of specific M1 and M2 cytokine markers of differentiation and may have impaired the ability to make immunological synapses and present antigens, down-regulating the expression of HLA-DR and CD209 antigens. Overall, our study supports the model that perturbation of miRNA cargo by PBDE-47 treatment contributes to the rewiring of cellular regulatory pathways capable of inducing perturbation of differentiation markers on naïve resting M(0) THP-1 macrophage-like cells.
Collapse
Affiliation(s)
- Valeria Longo
- Institute for Biomedical Research and Innovation, National Research Council of Italy (IRIB-CNR), Palermo, Italy
| | - Noemi Aloi
- Institute for Biomedical Research and Innovation, National Research Council of Italy (IRIB-CNR), Palermo, Italy
| | - Elena Lo Presti
- Institute for Biomedical Research and Innovation, National Research Council of Italy (IRIB-CNR), Palermo, Italy
| | - Antonino Fiannaca
- High Performance Computing and Networking Institute, National Research Council of Italy (ICAR-CNR), Palermo, Italy
| | - Alessandra Longo
- Institute for Biomedical Research and Innovation, National Research Council of Italy (IRIB-CNR), Palermo, Italy
| | - Giorgia Adamo
- Institute for Biomedical Research and Innovation, National Research Council of Italy (IRIB-CNR), Palermo, Italy
| | - Alfonso Urso
- High Performance Computing and Networking Institute, National Research Council of Italy (ICAR-CNR), Palermo, Italy
| | - Serena Meraviglia
- Department of Biomedicine, Neurosciences and Advanced Diagnostics, University of Palermo, Palermo, Italy
| | - Antonella Bongiovanni
- Institute for Biomedical Research and Innovation, National Research Council of Italy (IRIB-CNR), Palermo, Italy
| | - Fabio Cibella
- Institute for Biomedical Research and Innovation, National Research Council of Italy (IRIB-CNR), Palermo, Italy
| | - Paolo Colombo
- Institute for Biomedical Research and Innovation, National Research Council of Italy (IRIB-CNR), Palermo, Italy,*Correspondence: Paolo Colombo,
| |
Collapse
|
41
|
Turck D, Bohn T, Castenmiller J, De Henauw S, Hirsch‐Ernst KI, Maciuk A, Mangelsdorf I, McArdle HJ, Naska A, Pelaez C, Pentieva K, Siani A, Thies F, Tsabouri S, Vinceti M, Cubadda F, Frenzel T, Heinonen M, Marchelli R, Neuhäuser‐Berthold M, Poulsen M, Prieto Maradona M, Schlatter JR, van Loveren H, Colombo P, Noriega Fernández E, Knutsen HK. Safety of 2'-fucosyllactose (2'-FL) produced by a derivative strain (APC199) of Corynebacterium glutamicumATCC 13032 as a novel food pursuant to Regulation (EU) 2015/2283. EFSA J 2022; 20:e07647. [PMID: 36531695 PMCID: PMC9749449 DOI: 10.2903/j.efsa.2022.7647] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on 2'-fucosyllactose (2'-FL) as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF is mainly composed of the human-identical milk oligosaccharide (HiMO) 2'-FL, but it also contains d-lactose, l-fucose, 3-fucosyllactose, difucosyllactose, d-glucose and d-galactose. The NF is produced by fermentation with a genetically modified strain (APC199) of Corynebacterium glutamicum ATCC 13032. 2'-FL, when chemically synthesised or produced by fermentation with derivative strains of Escherichia coli K-12 DH1 or E. coli BL21 (DE3), is already authorised and included in the EU list of NFs. This application refers to a change in the production process and specifications, while target population, conditions of use and consequently, the anticipated intake remain unchanged. The information provided on the identity, production process, composition and specifications of the NF does not raise safety concerns. The intake of other carbohydrate-type compounds structurally related to 2'-FL is also considered of no safety concern. In line with other milk oligosaccharides that are natural components of human milk, the safety assessment of this NF is mainly based on the comparison between the intake of breastfed infants and the estimated intake as NF. Given that the NF would be consumed at the same extent as the already authorised 2'-FL, the Panel considers that the consumption of the NF at the proposed uses and use levels does not raise safety concerns. The Panel concludes that the NF is safe under the proposed conditions of use.
Collapse
|
42
|
Turck D, Bohn T, Castenmiller J, De Henauw S, Hirsch‐Ernst KI, Maciuk A, Mangelsdorf I, McArdle HJ, Naska A, Pelaez C, Pentieva K, Siani A, Thies F, Tsabouri S, Vinceti M, Cubadda F, Frenzel T, Heinonen M, Marchelli R, Neuhäuser‐Berthold M, Poulsen M, Prieto Maradona M, Schlatter JR, van Loveren H, Colombo P, Noriega Fernández E, Knutsen HK. Safety of 6'-sialyllactose (6'-SL) sodium salt produced by derivative strains of Escherichia coli BL21 (DE3) as a novel food pursuant to Regulation (EU) 2015/2283. EFSA J 2022; 20:e07645. [PMID: 36507098 PMCID: PMC9728050 DOI: 10.2903/j.efsa.2022.7645] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on 6'-sialyllactose (6'-SL) sodium salt as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF is mainly composed of the human-identical milk oligosaccharide (HiMO) 6'-SL, but it also contains d-lactose, 6'-sialyllactulose, sialic acid, N-acetyl-d-glucosamine and a small fraction of other related oligosaccharides. The NF is produced by fermentation with two genetically modified strains of Escherichia coli BL21 (DE3), the production strain and the optional degradation strain. The information provided on the identity, manufacturing process, composition and specifications of the NF does not raise safety concerns. The applicant intends to add the NF to a variety of foods, including infant formula and follow-on formula, food for special medical purposes and food supplements. The target population is the general population. In some scenarios at the maximum use levels, the estimated intakes per kg body weight were higher than the high average natural intake of 6'-SL from human milk. However, given the intrinsic nature of human milk oligosaccharides (HMOs), the wide range of intakes from human milk, and considering that infants are naturally exposed to similar amounts of these substances, the Panel considers that the consumption of the NF at the proposed conditions of use does not raise safety concerns. The intake of 6'-SL in breastfed infants on a body weight basis is also expected to be safe for other population groups. The intake of other carbohydrate-type compounds structurally related to 6'-SL is also considered of no safety concern. Food supplements are not intended to be used if other foods with added 6'-SL or human milk are consumed on the same day. The Panel concludes that the NF is safe under the proposed conditions of use.
Collapse
|
43
|
Longo V, Drago G, Longo A, Ruggieri S, Sprovieri M, Cibella F, Colombo P. A multipollutant low-grade exposure regulates the expression of miR-30b, Let-7a and miR-223 in maternal sera: Evidence from the NEHO cohort. Sci Total Environ 2022; 844:157051. [PMID: 35780881 DOI: 10.1016/j.scitotenv.2022.157051] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/15/2022] [Revised: 06/14/2022] [Accepted: 06/25/2022] [Indexed: 06/15/2023]
Abstract
There is growing evidence that environmental pollutants can induce epigenetic modifications altering the balance of miRNAs and inducing the onset of pathological conditions in animals. In this study, we measured the serum concentration of a suite of inorganic and organic pollutants (Cu, Zn, Se, Hg, HCB, p,p'-DDE, PCBs) and their association to serum miR-30b, miR-223 and Let-7a microRNA expression in 68 healthy pregnant women from the NEHO birth cohort sited in a highly industrialized area. The effects of the pollutants on the modulation of circulating miRNAs' expression were first investigated using linear continuous regression models with a single-compound approach showing that miR-223 expression was significantly associated with serum concentration of Se and Zn (pSe = 0.0336; pZn = 0.0225) and miR-30b was associated with Hg levels (pHg = 0.019). Furthermore, when contaminants were categorized into tertiles, miR-223 and miR-30b showed a positive association with higher tertiles of Zn, p,p'-DDE (pZn = 0.023; pDDE = 0.041) and Hg (pHg = 0.008), respectively. Moreover, Let-7a expression was exclusively influenced by medium tertiles levels of Se (low vs medium tertiles, p = 0.001). Simultaneous exposure to multi-pollutant mixture was approached by WQS regression model. Statistical analysis shows a driving effect of Zn, Se, Cu, Hg and HCB on significant increased expression of Let-7a (p = 0.045). Mercury and Se significantly amplified the expression for miR-30b (p = 0.038). Differently, the combined effect of p,p'-DDE, Zn and Se decreased miR-223 expression (p = 0.0001). The documented modified expression of circulating miRNAs in the serum of pregnant women, exposed to low-medium dose contaminants mixtures offers innovative early-warning approaches to human health risk assessment.
Collapse
Affiliation(s)
- Valeria Longo
- Institute for Biomedical Research and Innovation, National Research Council of Italy (IRIB-CNR), Via Ugo La Malfa 153, 90146 Palermo, Italy
| | - Gaspare Drago
- Institute for Biomedical Research and Innovation, National Research Council of Italy (IRIB-CNR), Via Ugo La Malfa 153, 90146 Palermo, Italy
| | - Alessandra Longo
- Institute for Biomedical Research and Innovation, National Research Council of Italy (IRIB-CNR), Via Ugo La Malfa 153, 90146 Palermo, Italy
| | - Silvia Ruggieri
- Institute for Biomedical Research and Innovation, National Research Council of Italy (IRIB-CNR), Via Ugo La Malfa 153, 90146 Palermo, Italy
| | - Mario Sprovieri
- Institute of Anthropic Impacts and Sustainability in Marine Environment, National Research Council of Italy (CNR-IAS), via del Mare 3, 91021 Torretta Granitola, Trapani, Italy
| | - Fabio Cibella
- Institute for Biomedical Research and Innovation, National Research Council of Italy (IRIB-CNR), Via Ugo La Malfa 153, 90146 Palermo, Italy
| | - Paolo Colombo
- Institute for Biomedical Research and Innovation, National Research Council of Italy (IRIB-CNR), Via Ugo La Malfa 153, 90146 Palermo, Italy.
| |
Collapse
|
44
|
Contieri R, Gobbo A, Paciotti M, Avolio P, Fasulo V, Saitta C, Uleri A, Valeri M, Colombo P, Saita A, Lazzeri M, Lughezzani G, Buffi N, Casale P, Guazzoni G, Hurle R. Accuracy of AUA and EAU risk stratification groups in predicting early recurrence in HG TA non-muscle invasive bladder cancer: a comparison analysis. EUR UROL SUPPL 2022. [DOI: 10.1016/s2666-1683(22)01022-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
45
|
Razali S, Bose A, Benetti C, Win Chong P, Miller M, Colombo P, Colombo G, Wui Wong T. Advanced Dome cellulose/alginate/chitosan composite matrix design with gastric and intestinal co-targeting capacities. Int J Pharm 2022; 628:122226. [PMID: 36191818 DOI: 10.1016/j.ijpharm.2022.122226] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2022] [Revised: 08/30/2022] [Accepted: 09/18/2022] [Indexed: 10/31/2022]
Abstract
Dome matrix was designed with gastric and intestinal targeting capacities using melatonin and caffeine as model drugs, and alginate, chitosan and cellulose as composite materials. The melatonin, caffeine and intermediate hydroxypropylmethylcelluose-based dispersible modules were prepared through compaction. Caffeine piled module was capped at both ends with melatonin void modules via intermediate dispersible modules into Dome matrix. Dispersion of intermediate module detached melatonin module from Dome matrix and had it floated in stomach providing a more complete melatonin release due to favorable pH-pKa relationship of dissolution medium and drug. With reference to the caffeine module, the detachment of melatonin module facilitated its gastrointestinal transit as a reduced size matrix, with majority of caffeine delivered in colon. The dual site-targeted and -release Dome matrix is applicable as reference oral carrier for pharmaceutical, nutraceutical, functional food and veterinary medicine where a complex formulation and performancein vivoare required.
Collapse
Affiliation(s)
- Sharipah Razali
- Non-Destructive Biomedical and Pharmaceutical Research Centre, Smart Manufacturing Research Institute, Universiti Teknologi MARA Selangor, 42300, Puncak Alam, Selangor, Malaysia; Particle Design Research Group, Faculty of Pharmacy, Universiti Teknologi MARA Selangor, 42300, Puncak Alam, Selangor, Malaysia
| | - Anirbandeep Bose
- Taab Biostudy Services, Jadavpur University, Jadavpur, Kolkata 32, India
| | - Camillo Benetti
- Non-Destructive Biomedical and Pharmaceutical Research Centre, Smart Manufacturing Research Institute, Universiti Teknologi MARA Selangor, 42300, Puncak Alam, Selangor, Malaysia; Food and Drug Department, University of Parma, Parma, Italy
| | - Pee Win Chong
- InQpharm Group Sdn Bhd, Plaza Mont Kiara, 2, Jalan Kiara, 50480, Kuala Lumpur, Malaysia
| | - Matthias Miller
- InQPharm Consumer Health GmbH, Waldseeweg 6, 13467 Berlin, Germany
| | - Paolo Colombo
- Food and Drug Department, University of Parma, Parma, Italy; PlumeStars srl, Parma, Italy
| | - Gaia Colombo
- Department of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy
| | - Tin Wui Wong
- Non-Destructive Biomedical and Pharmaceutical Research Centre, Smart Manufacturing Research Institute, Universiti Teknologi MARA Selangor, 42300, Puncak Alam, Selangor, Malaysia; Particle Design Research Group, Faculty of Pharmacy, Universiti Teknologi MARA Selangor, 42300, Puncak Alam, Selangor, Malaysia.
| |
Collapse
|
46
|
Maranghi F, Tassinari R, Tait S, Barletta B, Cinzia B, Silvia C, Colombo P, Longo A, Longo V, Di Felice G. P02-07 Integrated approach to evaluate (immuno)toxicity of BDE-47 in female Balb-c mice. Toxicol Lett 2022. [DOI: 10.1016/j.toxlet.2022.07.261] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
47
|
Quarta E, Esposti LD, Bettini R, Sonvico F, Catalucci D, Iafisco M, De Luca C, Trevisi G, Colombo P, Rossi A, Buttini F, Colombo G. Dry powder inhalation technology for heart targeting applied to calcium phosphate nanoparticles loaded with active substances. J Drug Deliv Sci Technol 2022. [DOI: 10.1016/j.jddst.2022.103719] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
48
|
Ma S, Liu X, Fu S, Zhao S, He P, Duan X, Yang Z, Jia D, Colombo P, Zhou Y. Direct ink writing of porous SiC ceramics with geopolymer as binder. Ann Ital Chir 2022. [DOI: 10.1016/j.jeurceramsoc.2022.08.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022]
|
49
|
Grazioli S, Mauri M, Rosi E, Villa F, Tizzoni F, Tarabelloni A, Trabattoni S, Mauri V, Colombo P, Molteni M, Nobile M. Use of machine learning on clinical questionnaires data to support the diagnostic classification of Attention DeficitHyperactivity Disorder: a personalized medicine approach. Eur Psychiatry 2022. [PMCID: PMC9566907 DOI: 10.1192/j.eurpsy.2022.441] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Introduction Attention Deficit / Hyperactivity Disorder (ADHD) is a highly prevalent neurodevelopmental condition characterized by inattention, motor hyperactivity and impulsivity. ADHD cognitive and behavioral presentation is characterized by a high heterogeneity (APA, 2013). Indeed, a complex diagnostic process, that considers several validated tools, is, to date, necessary. Objectives The main aim is to develop supervised machine learning (ML) algorithms that could be used to support the diagnostic process for ADHD, by identifying the most relevant features in discriminating between the presence or absence of the ADHD diagnosis in children. Methods We analyzed data from 342 children (Mean age: 8y 8m ± 1y; 61 F) referred for possible ADHD symptomatology. Assessments were performed by an expert clinician and through questionnaires: Social Responsiveness Scale (SRS), Child Behavior Checklist (CBCL), Conners Rating Scale for Parents (CPRS) and for Teachers (CTRS). Data were analyzed using a decision tree classifier and random forest algorithms. Results The decision tree model performed an accuracy of 0.71. The random forest model that was identified as the best tested, performed an accuracy of 0.77 (Figure 1) and it identified as most informative parent- and teacher-rated DSM-oriented ADHD symptoms (Figure 2). ![]()
Figure 1: Random forest confusion matrix and statistics. ![]()
Figure 2: Ranking of variables importance. Conclusions A random forest classifier could represent an effective algorithm to support the identification of ADHD children and to simplify the diagnostic process as an initial step. The use of supervised machine learning algorithms could be useful in helping the diagnostic process, highlighting the importance of a personalized medicine approach. Disclosure No significant relationships.
Collapse
|
50
|
Turck D, Bohn T, Castenmiller J, De Henauw S, Hirsch-Ernst KI, Maciuk A, Mangelsdorf I, McArdle HJ, Naska A, Pelaez C, Pentieva K, Siani A, Thies F, Tsabouri S, Vinceti M, Cubadda F, Frenzel T, Heinonen M, Marchelli R, Neuhäuser-Berthold M, Poulsen M, Prieto Maradona M, Schlatter JR, van Loveren H, Colombo P, Noriega Fernández E, Knutsen HK. Safety of 3-fucosyllactose (3-FL) produced by a derivative strain of Escherichia coli BL21 (DE3) as a Novel Food pursuant to Regulation (EU) 2015/2283. EFSA J 2022; 20:e07329. [PMID: 35646167 PMCID: PMC9131588 DOI: 10.2903/j.efsa.2022.7329] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
Abstract
Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on 3‐fucosyllactose (3‐FL) as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF is mainly composed of the human‐identical milk oligosaccharide (HiMO) 3‐FL, but it also contains d‐lactose, l‐fucose, d‐glucose and d‐galactose, and a small fraction of other related saccharides. The NF is produced by fermentation with a genetically modified strain of Escherichia coli BL21 (DE3). The information provided on the manufacturing process, composition and specifications of the NF does not raise safety concerns. The applicant intends to add the NF to a variety of foods, including infant formula and follow‐on formula, food for infants and young children, food for special medical purposes and food supplements. The target population is the general population. The anticipated daily intake of 3‐FL from both proposed and combined (authorised and proposed) uses at their respective maximum use levels in all population categories does not exceed the highest intake level of 3‐FL from human milk in infants on a body weight basis. The intake of 3‐FL in breastfed infants on a body weight basis is expected to be safe also for other population groups. The intake of other carbohydrate‐type compounds structurally related to 3‐FL is also considered of no safety concern. Food supplements are not intended to be used if other foods with added 3‐FL or human milk are consumed on the same day. The Panel concludes that the NF is safe under the proposed conditions of use.
Collapse
|